CL-82198 is a selective MMP-13 inhibitor. CL-82198 binds to the entire S1' pocket of MMP-13, which underlies its selectivity for MMP-13 and lack of inhibitory activity against other MMPs. CL-82198 may be utilized in osteoarthritis (OA) research.

Physicochemical Properties

Molecular Formula	C17H22N2O3
Molecular Weight	302.374
Exact Mass	302.163
CAS #	307002-71-7
Related CAS #	307002-71-7;1188890-36-9 (HCl);
PubChem CID	2777
Appearance	White to off-white solid powder
Boiling Point	537.1ºC at 760 mmHg
Flash Point	278.6ºC
LogP	3.405
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	4
Rotatable Bond Count	6
Heavy Atom Count	22
Complexity	358
Defined Atom Stereocenter Count	0
InChi Key	KUJQEQAVMNFFAO-UHFFFAOYSA-N
InChi Code	InChI=1S/C17H22N2O3/c20-17(16-13-14-5-1-2-6-15(14)22-16)18-7-3-4-8-19-9-11-21-12-10-19/h1-2,5-6,13H,3-4,7-12H2,(H,18,20)
Chemical Name	N-(4-morpholin-4-ylbutyl)-1-benzofuran-2-carboxamide
Synonyms	CL-82198; CL 82198; CL82198
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vitro	Significantly less LS174 cell migration occurs when CL-82198 (10 μM) is applied for 24 hours [1]. In hepatic stellate cells, CL-82198 lowers the amounts of TGF-β1 and CTGF [3].
ln Vivo	MLI-induced osteoarthritis is prevented and its progression is impeded by CL82198 (1–10 mg/kg; intraperitoneal injection; every other day for 12 weeks) [4].
Animal Protocol	Animal/Disease Models: 10weeks old C57BL/6J mice (undergoing MLI surgery) [4] Doses: 1, 5, 10 mg/kg body weight Route of Administration: intraperitoneal (ip) injection; every other day for 12 weeks Experimental Results: Prevention and mitigation Progression of MLI-induced osteoarthritis.
References	[1]. Matrix metalloproteinase-13 is regulated by toll-like receptor-9 in colorectal cancer cells and mediates cellular migration. Oncol Lett. 2011 May;2(3):483-488. [2]. MMP-13 deletion decreases profibrogenic molecules and attenuates N-nitrosodimethylamine-induced liver injury and fibrosis in mice. J Cell Mol Med. 2017 Dec;21(12):3821-3835. [3]. Nebulized hypertonic saline attenuates acute lung injury following trauma and hemorrhagic shock via inhibition of matrix metalloproteinase-13. Crit Care Med. 2012 Sep;40(9):2647-53. [4]. MMP13 is a critical target gene during the progression of osteoarthritis. Arthritis Res Ther. 2013 Jan 8;15(1):R5.
Additional Infomation	N-[4-(4-morpholinyl)butyl]-2-benzofurancarboxamide is a member of benzofurans.

Solubility Data

Solubility (In Vitro)

DMSO : ~100 mg/mL (~330.72 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 2.5 mg/mL (8.27 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.27 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (8.27 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	3.3072 mL	16.5360 mL	33.0721 mL
	5 mM	0.6614 mL	3.3072 mL	6.6144 mL
	10 mM	0.3307 mL	1.6536 mL	3.3072 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.